GenMark Diagnostics, Inc. designs and manufactures multiplex molecular diagnostic solutions to enhance patient care, improve quality metrics, and reduce the total cost-of-care for laboratory professionals, healthcare providers, and customers in the United States and internationally. It offers ePlex systems to streamline the diagnostic workflow from physician order entry to the release of the final report, automate and accelerate order entry and results reporting, notify practitioners that test results are available, enable operation on every shift, minimize system downtime and ensure patients and physicians have access to rapid test results, and reduce avoidable medical errors; ePlex software to support the needs of laboratory and healthcare systems, streamline tasks across the diagnostic process from order-to-report, improve productivity at every level, improve order-to-report turnaround time, reduce labor costs, and eliminate potential transcription errors with bi-directional LIS capabilities; XT-8 systems for processing multiple tests; ePlex panels that include respiratory pathogen and blood culture identification (BCID) Panels to identify the viral and bacterial organisms associated with upper respiratory infection, provide broad coverage of organisms that can lead to sepsis along with the resistance genes, and aid clinicians in the identification of bacterial and fungal organisms; and XT-8 panels to provide sensitive and specific respiratory virus detection with an optimized workflow to maximize laboratory efficiency. The company serves customers through distributors. GenMark Diagnostics, Inc. was formerly known as Osmetech plc and changed its name to GenMark Diagnostics, Inc. in June 2010. The company was incorporated in 2010 and is based in Carlsbad, California. As of April 21, 2021, GenMark Diagnostics, Inc. operates as a subsidiary of Roche Holding AG.